---
title: "Semaglutide improves atrial function and diastolic filling in obesity-related HFpEF: CMR substudy"
id: "nature-2-effects-of-semaglutide-on-cardiac-structure-and-function-in-heart-failure-with"
canonical_url: "https://medichelpline.com/clinical-feed/nature-2-effects-of-semaglutide-on-cardiac-structure-and-function-in-heart-failure-with"
content_type: "clinical_feed_article"
specialty: "Cardiology"
source_name: "Nature Medicine"
source_url: "https://www.nature.com/articles/s41591-026-04787-8"
published_at: "2026-11-08T12:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Semaglutide improves atrial function and diastolic filling in obesity-related HFpEF: CMR substudy
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/nature-2-effects-of-semaglutide-on-cardiac-structure-and-function-in-heart-failure-with
- **Specialty:** [Cardiology](https://medichelpline.com/clinical-feed/cardiology.md)
- **Primary Source:** Nature Medicine
- **Source URL:** [Original Journal Publication](https://www.nature.com/articles/s41591-026-04787-8)
- **Published At:** 2026-11-08T12:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- The prespecified cardiac magnetic resonance (CMR) substudy enrolled 49 participants from the randomized CAMEO-SEMA trial; 33 received **semaglutide** and 16 received placebo, and 28 were female. - Investigators obtained CMR at baseline and at 52 weeks, timed within one day of invasive exercise hemodynamic testing. - The primary CMR endpoint was change in **LA reservoir strain**; other prespecified endpoints included left ventricular filling dynamics quantified as early filling rate indexed to end-diastolic volume (**eFR/EDV**). - Compared with placebo, semaglutide increased LA reservoir strain by +5.7% (95% CI +0.3 to +9.7; P=0.037). - Semaglutide also increased **eFR/EDV** by +0.64 s−1 (95% CI +0.42 to +1.00; P<0.0001), indicating improved early diastolic filling indexed to chamber volume. - Improvements in LA reservoir strain correlated with reductions in exercise pulmonary artery wedge pressure (**PAWP**) (r=−0.46, P<0.001). - Improvements in eFR/EDV showed a stronger correlation with exercise PAWP reductions (r=−0.65, P<0.0001). - The treatment arm showed reductions in left ventricular mass, restoration toward more physiologic LV geometry, and improvements in right ventricular function and biventricular myocardial mechanics, as reported by the study team. - The authors noted these myocardial and chamber-level changes may help explain previously reported hemodynamic benefits of semaglutide in obesity-related **HFpEF**. - The ClinicalTrials.gov identifier for the parent trial is NCT05371496. The source did not report dosing details or some procedural specifics within the provided abstract text.
## Clinical Analysis & Structured Key Points
## Your privacy, your choice We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media, as well as to allow video information to be shared for both marketing, analytics and editorial purposes. By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection. See our [privacy policy](https://www.nature.com/info/privacy) for more information on the use of your personal data. Manage preferences for further information and to change your choices. Accept all cookies Reject optional cookies [Skip to main content](https://www.nature.com/articles/s41591-026-04787-8#content) Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Advertisement [ ![Nature Medicine](https://media.springernature.com/full/nature-cms/uploads/product/nm/header-95e59e63930e5d6009bad2c23a42ab2d.svg) ](https://www.nature.com/nm) * [ View all journals ](https://www.nature.com/siteindex) * [ Saved research ](https://www.nature.com/saved-research) * [ Search ](javascript:;) ## Search Search articles by subject, keyword or author Show results from All journals This journal Search [ Advanced search ](https://www.nature.com/search/advanced) ### Quick links * [Explore articles by subject](https://www.nature.com/subjects) * [Find a job](https://www.nature.com/naturecareers) * [Guide to authors](https://www.nature.com/authors/index.html) * [Editorial policies](https://www.nature.com/authors/editorial_policies/) * [Log in](https://idp.nature.com/auth/personal/springernature?redirect_uri=https://www.nature.com/articles/s41591-026-04787-8) * [ Content Explore content ](javascript:;) ## Explore content * [ Research articles ](https://www.nature.com/nm/research-articles) * [ Reviews & Analysis ](https://www.nature.com/nm/reviews-and-analysis) * [ News & Comment ](https://www.nature.com/nm/news-and-comment) * [ Podcasts ](https://www.nature.com/nm/podcast) * [ Current issue ](https://www.nature.com/nm/current-issue) * [ Collections ](https://www.nature.com/nm/collections) * [Follow us on Facebook ](https://www.facebook.com/Nature-Medicine-193691346949/) * [Follow us on X ](https://twitter.com/naturemedicine) * [ Subscribe ](https://www.nature.com/nm/subscribe) * [Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41591) * [ RSS feed ](https://www.nature.com/nm.rss) * [ About the journal ](javascript:;) ## About the journal * [ Aims & Scope ](https://www.nature.com/nm/aims) * [ Journal Information ](https://www.nature.com/nm/journal-information) * [ Editors ](https://www.nature.com/nm/editors) * [ Journal Metrics ](https://www.nature.com/nm/journal-impact) * [ Research Cross-Journal Editorial Team ](https://www.nature.com/nm/research-cross-journal-editorial-team) * [ Reviews Cross-Journal Editorial Team ](https://www.nature.com/nm/reviews-cross-journal-editorial-team) * [ Statistical Advisory Panel ](https://www.nature.com/nm/statistics-advisory-panel) * [ Our publishing models ](https://www.nature.com/nm/our-publishing-models) * [ Editorial Values Statement ](https://www.nature.com/nm/editorial-values-statement) * [ Editorial Policies ](https://www.nature.com/nm/editorial-policies) * [ Content Types ](https://www.nature.com/nm/content) * [ Web Feeds ](https://www.nature.com/nm/web-feeds) * [ Contact ](https://www.nature.com/nm/contact) * [ Publish with us ](javascript:;) ## Publish with us * [ Submission Guidelines ](https://www.nature.com/nm/submission-guidelines) * [ For Reviewers ](https://www.nature.com/nm/for-reviewers) * [ Language editing services ](https://authorservices.springernature.com/go/sn/?utm_source=For+Authors&utm_medium=Website_Nature&utm_campaign=Platform+Experimentation+2022&utm_id=PE2022) * [Open access funding](https://www.nature.com/nm/open-access-funding) * [Submit manuscript ](https://mts-nmed.nature.com/cgi-bin/main.plex) * [ Subscribe ](https://www.nature.com/nm/subscribe) * [ Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41591) * [ RSS feed ](https://www.nature.com/nm.rss) 1. [nature](https://www.nature.com/) 2. [nature medicine](https://www.nature.com/nm) 3. [articles](https://www.nature.com/nm/articles?type=article) 4. article * Article * Published: 08 November 2026 # Effects of semaglutide on cardiac structure and function in heart failure with preserved ejection fraction and obesity: a pre-specified cardiac magnetic resonance substudy of the CAMEO-SEMA trial * [Fahime Ghanbari](https://www.nature.com/articles/s41591-026-04787-8#auth-Fahime-Ghanbari-Aff1)[1](https://www.nature.com/articles/s41591-026-04787-8#Aff1), * [Yogesh N. V. Reddy](https://www.nature.com/articles/s41591-026-04787-8#auth-Yogesh_N__V_-Reddy-Aff1) [ORCID: orcid.org/0000-0001-5322-0902](https://orcid.org/0000-0001-5322-0902)[1](https://www.nature.com/articles/s41591-026-04787-8#Aff1), * [Milton Packer](https://www.nature.com/articles/s41591-026-04787-8#auth-Milton-Packer-Aff2)[2](https://www.nature.com/articles/s41591-026-04787-8#Aff2), * [Arnold Ng](https://www.nature.com/articles/s41591-026-04787-8#auth-Arnold-Ng-Aff3)[3](https://www.nature.com/articles/s41591-026-04787-8#Aff3), * [Rickey Carter](https://www.nature.com/articles/s41591-026-04787-8#auth-Rickey-Carter-Aff4) [ORCID: orcid.org/0000-0002-0818-273X](https://orcid.org/0000-0002-0818-273X)[4](https://www.nature.com/articles/s41591-026-04787-8#Aff4), * [Michael D. Jensen](https://www.nature.com/articles/s41591-026-04787-8#auth-Michael_D_-Jensen-Aff5) [ORCID: orcid.org/0000-0001-5589-8389](https://orcid.org/0000-0001-5589-8389)[5](https://www.nature.com/articles/s41591-026-04787-8#Aff5), * [Tim Leiner](https://www.nature.com/articles/s41591-026-04787-8#auth-Tim-Leiner-Aff6) [ORCID: orcid.org/0000-0003-1885-5499](https://orcid.org/0000-0003-1885-5499)[6](https://www.nature.com/articles/s41591-026-04787-8#Aff6) & * … * [Barry A. Borlaug](https://www.nature.com/articles/s41591-026-04787-8#auth-Barry_A_-Borlaug-Aff1) [ORCID: orcid.org/0000-0001-9375-0596](https://orcid.org/0000-0001-9375-0596)[1](https://www.nature.com/articles/s41591-026-04787-8#Aff1) Show authors [_Nature Medicine_](https://www.nature.com/nm) (2026) [Cite this article](https://www.nature.com/articles/s41591-026-04787-8#citeas) Save article [ View saved research ](https://www.nature.com/saved-research) We’re sharing this article early to provide faster access to peer-reviewed, accepted research. It is citable and carries a permanent DOI. This version is subject to further edits and will be replaced automatically by the final Version of Record. All legal disclaimers apply. ## Abstract Glucagon-like peptide-1 receptor agonists improve symptoms in patients with obesity and heart failure with preserved ejection fraction (HFpEF). We recently demonstrated that semaglutide reduces exertional pulmonary artery wedge pressure (PAWP) in obesity-related HFpEF, but potential effects of semaglutide on cardiac structure and function that may underlie these hemodynamic improvements remain unclear. In this prespecified cardiovascular magnetic resonance (CMR) substudy of the randomized CAMEO-SEMA trial, 49 participants (33 semaglutide, 16 placebo, 28 female) underwent CMR at baseline and 52 weeks, within 1 day of invasive exercise hemodynamic assessment. The prespecified primary CMR endpoint was change in left atrial (LA) reservoir strain; other prespecified CMR endpoints included LV filling dynamics, which were assessed by early filling rate indexed to end-diastolic volume (eFR/EDV). Compared with placebo, semaglutide improved LA reservoir strain (+5.7% [95% CI, +0.3 to +9.7]; P=0.037) and eFR/EDV (+0.64 s−1 [95% CI, +0.42 to +1.00]; P<0.0001). Improvements in LA reservoir strain and LV filling dynamics were associated with reductions in exercise PAWP (r=−0.46, P<0.001 and r=−0.65, P<0.0001, respectively). With respect to other prespecified CMR endpoints, semaglutide reduced LV mass, restored more physiologic LV geometry, and improved right ventricular function and biventricular myocardial mechanics. The results of this CMR substudy indicate that in patients with obesity-related HFpEF, semaglutide improves LA function and LV diastolic filling dynamics, identifying improvements in myocardial function that may contribute to semaglutide’s improvement of hemodynamics. ClinicalTrials.gov number: [NCT05371496](https://clinicaltrials.gov/study/NCT05371496). This is a preview of subscription content, [access via your institution](https://wayf.springernature.com?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41591-026-04787-8) ## Access options [ Access through your institution ](https://wayf.springernature.com?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41591-026-04787-8) Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription 32.70 € / 30 days cancel any time [Learn more](https://shop.nature.com/products/plus/?region=ROW) Subscribe to this journal Receive 12 print issues and online access 251.40 € per year only 20.95 € per issue [Learn more](https://www.nature.com/nm/subscribe) Rent or buy this article Prices vary by article type $1.95 to $39.95 [Learn more](https://www.nature.com/articles/s41591-026-04787-8.epdf?no_publisher_access=1&r3_referer=nature) Prices may be subject to local taxes which are calculated during checkout ### Additional access options: * [Log in](https://idp.nature.com/auth/personal/springernature?client_id=grover&redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41591-026-04787-8) * [Learn about institutional subscriptions](https://www.springernature.com/gp/librarians/licensing/license-options) * [Read our FAQs](https://support.nature.com/en/support/home) * [Contact customer support](https://www.springernature.com/gp/contact) ### Similar content being viewed by others ![](https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41591-026-04762-3/MediaObjects/41591_2026_4762_Fig1_HTML.png) ### [Hemodynamic effects of semaglutide in individuals with heart failure with preserved ejection fraction and obesity: a placebo-controlled randomized clinical trial ](https://www.nature.com/articles/s41591-026-04762-3?fromPaywallRec=true) Article 08 November 2026 ![](https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41366-024-01646-9/MediaObjects/41366_2024_1646_Fig1_HTML.png) ### [Semaglutide effects on safety and cardiovascular outcomes in patients with overweight or obesity: a systematic review and meta-analysis ](https://www.nature.com/articles/s41366-024-01646-9?fromPaywallRec=true) Article 12 October 2024 ![](https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs44325-026-00146-1/MediaObjects/44325_2026_146_Fig1_HTML.png) ### [Semaglutide cardiovascular outcomes align more closely with attained dose than achieved weight loss ](https://www.nature.com/articles/s44325-026-00146-1?fromPaywallRec=true) Article Open access 10 July 2026 ### Explore related subjects Discover the latest articles and news in related subjects. * [Heart failure](https://www.nature.com/subjects/heart-failure) * [Medical research](https://www.nature.com/subjects/medical-research) * [Obesity-Related Heart Failure Mechanisms and Treatments](https://www.nature.com/subjects/obesity-related-heart-failure-mechanisms-and-treatments) ## Author information ### Authors and Affiliations 1. Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA Fahime Ghanbari, Yogesh N. V. Reddy & Barry A. Borlaug 2. Baylor University Medical Center, Dallas TX USA and Imperial College, London, UK Milton Packer 3. Princess Alexandra Hospital, The University of Queensland, Brisbane, QLD, Australia Arnold Ng 4. Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL, USA Rickey Carter 5. Division of Endocrinology, Diabetes, and Metabolism, Mayo Clinic, Rochester, MN, USA Michael D. Jensen 6. Department of Radiology, Mayo Clinic, Rochester, MN, USA Tim Leiner Authors 1. Fahime Ghanbari [View author publications](https://www.nature.com/search?author=Fahime%20Ghanbari) Search author on:[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Fahime%20Ghanbari)[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Fahime%20Ghanbari%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en) 2. Yogesh N. V. Reddy [View author publications](https://www.nature.com/search?author=Yogesh%20N.%20V.%20Reddy) Search author on:[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Yogesh%20N.%20V.%20Reddy)[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Yogesh%20N.%20V.%20Reddy%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en) 3. Milton Packer [View author publications](https://www.nature.com/search?author=Milton%20Packer) Search author on:[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Milton%20Packer)[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Milton%20Packer%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en) 4. Arnold Ng [View author publications](https://www.nature.com/search?author=Arnold%20Ng) Search author on:[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Arnold%20Ng)[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Arnold%20Ng%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en) 5. Rickey Carter [View author publications](https://www.nature.com/search?author=Rickey%20Carter) Search author on:[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Rickey%20Carter)[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Rickey%20Carter%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en) 6. Michael D. Jensen [View author publications](https://www.nature.com/search?author=Michael%20D.%20Jensen) Search author on:[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Michael%20D.%20Jensen)[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Michael%20D.%20Jensen%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en) 7. Tim Leiner [View author publications](https://www.nature.com/search?author=Tim%20Leiner) Search author on:[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Tim%20Leiner)[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Tim%20Leiner%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en) 8. Barry A. Borlaug [View author publications](https://www.nature.com/search?author=Barry%20A.%20Borlaug) Search author on:[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Barry%20A.%20Borlaug)[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Barry%20A.%20Borlaug%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en) ### Corresponding author Correspondence to Barry A. Borlaug. ## Supplementary information ### [Supplementary Information (download PDF )](https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-026-04787-8/MediaObjects/41591_2026_4787_MOESM1_ESM.pdf) Supplementary Note. ### [Reporting Summary (download PDF )](https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-026-04787-8/MediaObjects/41591_2026_4787_MOESM2_ESM.pdf) ### [Peer Review Information (download PDF )](https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-026-04787-8/MediaObjects/41591_2026_4787_MOESM3_ESM.pdf) Peer Review File. ## Source data ### [Source Data Fig. 1 (download XLSX )](https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-026-04787-8/MediaObjects/41591_2026_4787_MOESM4_ESM.xlsx) Source Data Fig. 1. ### [Source Data Fig. 2 (download XLSX )](https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-026-04787-8/MediaObjects/41591_2026_4787_MOESM5_ESM.xlsx) Source Data Fig. 2. ### [Source Data Fig. 3 (download XLSX )](https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-026-04787-8/MediaObjects/41591_2026_4787_MOESM6_ESM.xlsx) Source Data Fig. 3. ### [Source Data Extended Fig.2 (download XLSX )](https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-026-04787-8/MediaObjects/41591_2026_4787_MOESM7_ESM.xlsx) Source Data Extended Fig.2. ## Rights and permissions [Reprints and permissions](https://s100.copyright.com/AppDispatchServlet?title=Effects%20of%20semaglutide%20on%20cardiac%20structure%20and%20function%20in%20heart%20failure%20with%20preserved%20ejection%20fraction%20and%20obesity%3A%20a%20pre-specified%20cardiac%20magnetic%20resonance%20substudy%20of%20the%20CAMEO-SEMA%20trial&author=Fahime%20Ghanbari%20et%20al&contentID=10.1038%2Fs41591-026-04787-8&copyright=The%20Author%28s%29%2C%20under%20exclusive%20licence%20to%20Springer%20Nature%20America%2C%20Inc.&publication=1078-8956&publicationDate=2026-11-08&publisherName=SpringerNature&orderBeanReset=true) ## About this article [![Check for updates. Verify currency and authenticity via CrossMark](https://www.nature.com/articles/s41591-026-04787-8)](https://crossmark.crossref.org/dialog/?doi=10.1038/s41591-026-04787-8) ### Cite this article Ghanbari, F., Reddy, Y.N.V., Packer, M. _et al._ Effects of semaglutide on cardiac structure and function in heart failure with preserved ejection fraction and obesity: a pre-specified cardiac magnetic resonance substudy of the CAMEO-SEMA trial. _Nat Med_ (2026). https://doi.org/10.1038/s41591-026-04787-8 [Download citation](https://citation-needed.springer.com/v2/references/10.1038/s41591-026-04787-8?format=refman&flavour=citation) * Received: 15 September 2026 * Accepted: 29 October 2026 * Published: 08 November 2026 * DOI: https://doi.org/10.1038/s41591-026-04787-8 ### Share this article Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy shareable link to clipboard Provided by the Springer Nature SharedIt content-sharing initiative [ Access through your institution ](https://wayf.springernature.com?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41591-026-04787-8) [ Buy or subscribe ](https://www.nature.com/articles/s41591-026-04787-8#access-options) ## Associated content ### [Hemodynamic effects of semaglutide in individuals with heart failure with preserved ejection fraction and obesity: a placebo-controlled randomized clinical trial](https://www.nature.com/articles/s41591-026-04762-3) * Barry A. Borlaug * Michael D. Jensen * Rickey E. Carter Nature Medicine Article 08 Nov 2026 ## Sections * [Abstract](https://www.nature.com/articles/s41591-026-04787-8#Abs1) * [Author information](https://www.nature.com/articles/s41591-026-04787-8#author-information)
## Related Clinical Research

- [GLP-1 drugs tied to lower diabetes progression and cardiovascular events than metformin](https://medichelpline.com/clinical-feed/aha-news-4-glp-1-meds-linked-to-lower-diabetes-heart-risks-than-standard-diabetes.md)
- [Cardiovascular outcomes of GLP-1 receptor agonists: systematic review findings](https://medichelpline.com/clinical-feed/pubmed-42033237.md) (DOI: 10.1093/ajhp/zxag121)
- [Safiglipron vs dapagliflozin in type 2 diabetes: phase 3 randomized double-blind OUTSTAND-2 results](https://medichelpline.com/clinical-feed/nature-0-oral-small-molecule-glp-1ra-safiglipron-versus-dapagliflozin-in-type-2-diabetes.md)
- [GLP-1 Receptor Agonists and Pulmonary Hypertension: Mechanistic Rationale and Evidence Gaps](https://medichelpline.com/clinical-feed/pubmed-42747605.md) (DOI: 10.1007/s00408-026-00939-2)
- [Moving Forward: The Future of GLP-1 Therapies](https://medichelpline.com/clinical-feed/endocrine-news-18-moving-forward-the-future-of-glp-1-therapies.md)

## Navigation
- [← Back to Cardiology Feed](https://medichelpline.com/clinical-feed/cardiology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.